会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 12. 发明申请
    • Immunomodulating heterocyclic compounds
    • US20070021428A1
    • 2007-01-25
    • US10547448
    • 2004-03-10
    • Ian Matthews
    • Ian Matthews
    • A61K31/503C07D487/02
    • C07D487/04C07D519/00
    • Compounds of formula (I) are inhibitors of CD80 and useful in immunomodulation therapy: wherein R1 and R3 independently represent H; F; CI; Br; —NO2; —CN; C1-C6 alkyl optionally substituted by F or Cl; or C1-C6 alkoxy optionally substituted by F; R4 represents a carboxylic acid group (—COOH) or an ester thereof, or —C(═O)NR6R7, —NR7C(═O)R6, —NR7C(═O)OR6, —NHC(═O)NR7R6 or —NHC(═S)NR7R6 wherein R6 represents H, or a radical of formula -(Alk)m-Q wherein m is 0 or 1, Alk is an optionally substituted divalent straight or branched C1-C12 alkylene, or C2-C12 alkenylene, or C2-C12 alkynylene radical or a divalent C3-C12 carbocyclic radical, any of which radicals may contain one or more —O—, —S— or —N(R8)— links wherein R8, represents H or C1-C4 alkyl, C3-C4 alkenyl, C3-C4 alkynyl, or C3-C6 cycloalkyl, and Q represents H; —NR9R10 wherein R9 and R10 independently represents H; C1-C4 alkyl; C3-C4 alkenyl; C3-C4 alkynyl; C3-C6 cycloalkyl; an ester group; an optionally substituted carbocyclic or heterocyclic group; or R9 and R10 form a ring when taken together with the nitrogen to which they are attached, which ring is optionally substituted; and R7 represents H or C1-C6 alkyl; or when taken together with the atom or atoms to which they are attached R6 and R7 form an optionally substituted monocyclic heterocyclic ring having 5, 6 or 7 ring atoms; and X represents a bond or a divalent radical of formula —(Z)n-(Alk)- or -(Alk)-(Z)n— wherein Z represents —O—, —S— or —NH—, Alk is as defined in relation to R6, and n is 0 or 1.
    • 15. 发明申请
    • METHODS
    • 方法
    • WO2003016905A2
    • 2003-02-27
    • PCT/GB2002/003753
    • 2002-08-15
    • AVIDEX LIMITEDJAKOBSEN, Bent, Karsten
    • JAKOBSEN, Bent, Karsten
    • G01N33/53
    • G01N33/505
    • The present invention provides a method for determining whether a T cell reacts with a predetermined Major Histocompatibility Complex (MHC) type. In the method, a sample comprising said T cell is brought into contat with a plurality of molecules of said MHC type, each MHC molecule being complexed with a peptide antigen whose contribution to a T cell receptor binding the MHC-peptide antigen complex is minimised. Whether said plurality of MHC molecules causes activation of the T cell is then determined. The method can assess allo-specific T cell activity, and may be used in matching transplant and donor patients, as well as in monitoring alloreactive responses following a transplant operation.
    • 本发明提供了一种用于确定T细胞是否与预定的主要组织相容性复合物(MHC)类型反应的方法。 在该方法中,将包含所述T细胞的样品与多个所述MHC类型的分子连接,每个MHC分子与肽抗原复合,其对结合MHC-肽抗原复合物的T细胞受体的贡献最小化。 然后确定所述多个MHC分子是否导致T细胞的激活。 该方法可以评估异体特异性T细胞活性,并且可用于匹配移植和供体患者,以及在移植手术后监测同种异体反应性反应。
    • 19. 发明申请
    • IMMUNOMODULATING HETEROCYCLIC COMPOUNDS
    • 免疫调节杂环化合物
    • WO2004081011A1
    • 2004-09-23
    • PCT/GB2004/001008
    • 2004-03-10
    • AVIDEX LIMITEDMATHEWS, Ian, Richard
    • MATHEWS, Ian, Richard
    • C07D487/04
    • C07D487/04C07D519/00
    • Compounds of formula (I) are inhibitors of CD80 and useful in immunomodulation therapy: wherein R 1 and R 3 independently represent H; F; CI; Br; -NO 2 ; -CN; C 1 -C 6 alkyl optionally substituted by F or Cl; or C 1 -C 6 alkoxy optionally substituted by F; R 4 represents a carboxylic acid group (-COOH) or an ester thereof, or -C(=O)NR 6 R 7 , -NR 7 C(=O)R 6 , -NR 7 C(=O)OR 6 , -NHC(=O)NR 7 R 6 or -NHC(=S)NR 7 R 6 wherein R 6 represents H, or a radical of formula - (Alk) m -Q wherein m is 0 or 1, Alk is an optionally substituted divalent straight or branched C 1 -C 12 alkylene, or C 2 -C 12 alkenylene, or C 2 -C 12 alkynylene radical or a divalent C 3 -C 12 carbocyclic radical, any of which radicals may contain one or more -O-, -S- or -N(R 8 )- links wherein R 8 represents H or C 1 -C 4 alkyl, C 3- ­C 4 alkenyl, C 3 -C 4 alkynyl, or C 3 -C 6 cycloalkyl, and Q represents H; -NR 9 R 10 wherein R 9 and R 10 independently represents H; C 1 -C 4 alkyl; C 3 -C 4 alkenyl; C 3 -C 4 alkynyl; C 3 -C 6 cycloalkyl; an ester group; an optionally substituted carbocyclic or heterocyclic group; or R 9 and R 10 form a ring when taken together with the nitrogen to which they are attached, which ring is optionally substituted; and R 7 represents H or C 1 -C 6 alkyl; or when taken together with the atom or atoms to which they are attached R 6 and R 7 form an optionally substituted monocyclic heterocyclic ring having 5, 6 or 7 ring atoms; and X represents a bond or a divalent radical of formula - (Z) n -(Alk)- or - (Alk)-(Z) n - ­wherein Z represents -O-, -S- or -NH-, Alk is as defined in relation to R 6 and n is 0 or 1.
    • 式(I)化合物是CD80的抑制剂,可用于免疫调节治疗:其中R1和R3独立地表示H; F; CI; BR; NO 2; -CN; 任选被F或Cl取代的C 1 -C 6烷基; 或任选被F取代的C 1 -C 6烷氧基; 或-C(= O)NR 6 R 7,-NR 7 C(= O)R 6,-NR 7 C(= O)OR 6,-NHC(= O)NR 7 R 6或-NHC (= S)NR 7 R 6,其中R 6表示H,或式 - (Alk)mQ基团,其中m为0或1,Alk为任选取代的二价直链或支链C 1 -C 12亚烷基或C 2 -C 12亚烯基, C 12亚炔基或二价C 3 -C 12碳环基团,其中任何基团可以含有一个或多个-O - , - S-或-N(R 8) - 键,其中R 8表示H或C 1 -C 4烷基,C 3 -C 4烯基 ,C 3 -C 4炔基或C 3 -C 6环烷基,Q表示H; -NR 9 R 10,其中R 9和R 10独立地表示H; C 1 -C 4烷基; C3-C4烯基; C3-C4炔基; C3-C6环烷基; 酯基; 任选取代的碳环或杂环基; 当与它们所连接的氮一起取代时,R 9和R 10形成环,该环任选被取代; 并且R 7表示H或C 1 -C 6烷基; 或者当与它们所连接的原子或原子一起时,R6和R7形成任选取代的具有5,6或7个环原子的单环杂环; 并且X表示式 - (Z)n-(Alk) - 或 - (Alk) - (Z)n-的键或二价基团,其中Z表示-O - , - S-或-NH-,Alk为 关于R6定义,n为0或1。